STOCK TITAN

CNTA Insider Notice — 25,000 Shares via UBS on NASDAQ (Sep 10, 2025)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Centessa Pharmaceuticals plc (CNTA) reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/10/2025 on NASDAQ with an aggregate market value of $550,000.00. The shares were acquired and paid for on 09/10/2025 by exercise of a stock option and payment in cash. The filing lists 134,073,436 shares outstanding. The filing also discloses a sale the prior day: 24,792 shares sold on 09/09/2025 for gross proceeds of $495,840.00 by Tia Bush. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1/trading-plan language.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Rule 144 notice showing a small insider option exercise and planned sale; immaterial to capitalization.

The filing documents a proposed sale of 25,000 shares (about 0.019% of the stated 134,073,436 shares outstanding), following an exercise of options and same-day cash payment. The transaction appears procedural and compliant with Rule 144; the size relative to outstanding shares suggests negligible dilution or market impact. Prior day sale of 24,792 shares with similar proceeds indicates consecutive liquidity events by related parties. No earnings, debt, or operational disclosures are included, limiting investor inference.

TL;DR: Filing reflects standard insider reporting and attestation; raises routine governance transparency points.

This Form 144 provides required public notice of proposed insider sales and an attestation about material nonpublic information, which supports regulatory transparency. The disclosure that the shares were acquired via option exercise and paid in cash is appropriate for tracking insider compensation realizations. The filing does not disclose any 10b5-1 plan adoption date or additional governance context, so reviewers cannot confirm whether sales follow a pre-established trading plan.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Centessa (CNTA) disclose?

The Form 144 discloses a proposed sale of 25,000 common shares on 09/10/2025 via UBS on NASDAQ with aggregate market value of $550,000.00.

How were the 25,000 shares acquired according to the filing?

The shares were acquired on 09/10/2025 by exercise of a stock option from the issuer and paid for in cash on that date.

Did the filer report any recent sales of Centessa shares?

Yes. The filing shows that Tia Bush sold 24,792 shares on 09/09/2025 for gross proceeds of $495,840.00.

What is the number of Centessa shares outstanding listed in the filing?

The filing lists 134,073,436 shares outstanding.

Does the filing indicate the presence of material nonpublic information?

The person for whose account the securities are to be sold represents by signing the notice that they do not know any material adverse information that has not been publicly disclosed.
Centessa Pharmaceuticals Plc

NASDAQ:CNTA

CNTA Rankings

CNTA Latest News

CNTA Latest SEC Filings

CNTA Stock Data

3.31B
133.70M
0.49%
93.69%
3.93%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE